Carl Linnaeus

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

Retrieved on: 
Wednesday, April 3, 2024
Sustainability, Waltham Petcare Science Institute, Incineration, Environment, Partnership, History, Carbon, Carl Linnaeus, Pet, RCVS

BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. 

Key Points: 
  • BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health , through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute , today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere.
  • These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere.
  • Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come.
  • "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical.

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

Retrieved on: 
Wednesday, April 3, 2024
Sustainability, Waltham Petcare Science Institute, Incineration, Environment, Partnership, History, Carbon, Carl Linnaeus, Pet, RCVS

BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. 

Key Points: 
  • BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health , through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute , today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere.
  • These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere.
  • Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come.
  • "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical.

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma

Retrieved on: 
Thursday, January 19, 2023
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Therapy, Patient, FDA, MD, Cancer, Pembrolizumab, Pharmaceutical industry, Carl Linnaeus

HADDONFIELD, N.J., Jan. 19, 2023 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

Key Points: 
  • HADDONFIELD, N.J., Jan. 19, 2023 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.
  • The FDA's Office of Orphan Drug Products grants orphan drug status to support drug candidates in development for underserved patient populations or rare disorders that affect fewer than 200,000 people in the United States.
  • Orphan drug designation provides certain benefits, including market exclusivity upon FDA approval, exemption of FDA application fees, and tax credits for qualified clinical trials.
  • "We are extremely pleased to have received orphan drug designation for cutaneous melanoma from the FDA.

Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office

Retrieved on: 
Wednesday, September 21, 2022
Therapy, Trial of the century, Human, MD, GPER, Neoplasm, Quantum chemistry composite methods, Partnership, Patient, CEO, USPTO, Patent, Upstart, Perelman School of Medicine at the University of Pennsylvania, Multimedia, University, PCI, Penn Center, Innovation, Pharmaceutical industry, Carl Linnaeus, Cancer

HADDONFIELD, N.J., Sept. 21, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on June 28, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,369,618 ('618 patent) entitled "Compounds, Compositions Methods for Prevention and/or Treatment of Cancer".

Key Points: 
  • "We are extremely pleased that the USPTO has issued this critical patent, the third essential patent in our GPER agonist patent portfolio," commented Patrick Mooney, MD, CEO of Linnaeus.
  • "We believe that the issued claims will provide critical market protection for LNS8801 through at least 2037.
  • As we continue to collect very promising data from our clinical trials of LNS8001, we plan to prosecute the '618 patent on a worldwide basis."
  • Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors.

Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting

Retrieved on: 
Monday, June 6, 2022
Upstart, Human, Biomarker, Toxicity, CEO, Partnership, ASCO, Innovation, Toxic leukoencephalopathy, Therapy, Multimedia, University, Penn Center, Pembrolizumab, Patient, ICI, University of Pennsylvania Smell Identification Test, Infrared spectroscopy correlation table, Poster, MD, Clinical trial, Population, GPER, Neoplasm, PCI, Safety, Pharmaceutical industry, Vaccine, Carl Linnaeus

HADDONFIELD, N.J., June 6, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination with pembrolizumab in patients who have developed secondary resistance to antiPD-1/L1 therapy at the 2022 ASCO Annual Meeting.

Key Points: 
  • HADDONFIELD, N.J., June 6, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination with pembrolizumab in patients who have developed secondary resistance to antiPD-1/L1 therapy at the 2022 ASCO Annual Meeting.
  • These biomarkers are being further validated and will aid in the selection of patients in future clinical studies.
  • "We are very pleased to showcase these data at ASCO," commented Patrick Mooney, MD, CEO of Linnaeus.
  • Additionally, LNS8801 has demonstrated target engagement, c-Myc protein depletion, and clinical benefit in some patients with advanced cancer.

Linnaeus Therapeutics Announces Presentation of Pre-Clinical Data of LNS8801 at 2022 AACR Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
Penn Center, Therapy, Human, Cell death, Trial of the century, Multimedia, Upstart, AACR, Research, Doctor of Philosophy, Columbia University, Uveal melanoma, PCI, CEO, Perelman School of Medicine at the University of Pennsylvania, Columbia University Irving Medical Center, Poster, Neoplasm, Innovation, MD, ASCO, GPER, University, Patient, Partnership, Vaccine, Medical imaging, Carl Linnaeus

Ambrosini and colleagues have demonstrated that LNS8801 has potent anti-cancer activities in models of uveal melanoma cells.

Key Points: 
  • Ambrosini and colleagues have demonstrated that LNS8801 has potent anti-cancer activities in models of uveal melanoma cells.
  • "We are extremely pleased to showcase these data at AACR," commented Patrick Mooney, MD, CEO of Linnaeus.
  • "These data demonstrate that LNS8801 has activity in preclinical models of uveal melanoma in vitro and in vivo.
  • Importantly, these data are consistent with the clinical data in our on-going studies of LNS8801 in advanced cancer patients.

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma

Retrieved on: 
Wednesday, April 6, 2022
Penn Center, Therapy, National, Human, Partnership, Trial of the century, National Cancer Institute, Multimedia, Carl Linnaeus, Upstart, Cancer, Uveal melanoma, PCI, Perelman School of Medicine at the University of Pennsylvania, Neoplasm, Innovation, MD, Small business, NCI, GPER, University, Patient, Pembrolizumab, Mooney, Pharmaceutical industry

The award will help fund the clinical development of its lead compound, LNS8801, which targets a G protein-coupled receptor (GPER), for the treatment of metastatic cutaneous and uveal melanoma both as a monotherapy and in combination with pembrolizumab.

Key Points: 
  • The award will help fund the clinical development of its lead compound, LNS8801, which targets a G protein-coupled receptor (GPER), for the treatment of metastatic cutaneous and uveal melanoma both as a monotherapy and in combination with pembrolizumab.
  • "This award will allow us to further advance LNS8801 as a potentially safe and effective oral therapeutic for the treatment of metastatic cutaneous and uveal melanoma.
  • We thank the NCI for their ongoing support and belief in the potential of LNS8801 to help patients with cancer."
  • Additionally, LNS8801 has demonstrated target engagement, c-Myc protein depletion, and clinical benefit in patients with advanced cancer.

Infomaker Wins the Linnaeus University Partner of the Year Award

Retrieved on: 
Thursday, March 14, 2019
Biology, Geography of Sweden, Botanists, Botanical nomenclature, Arachnologists, Carl Linnaeus, Phycologists, Terminologists, Linnaeus University, Kalmar

BLOOMINGTON, Minn., March 14, 2019 /PRNewswire-PRWeb/ -- Infomaker, a NEWSCYCLE Solutions company, has been awarded the Linnaeus University Partner of the Year award.

Key Points: 
  • BLOOMINGTON, Minn., March 14, 2019 /PRNewswire-PRWeb/ -- Infomaker, a NEWSCYCLE Solutions company, has been awarded the Linnaeus University Partner of the Year award.
  • The university, which is based in Vxj and Kalmar, Sweden, grants this award to recognize companies that have shown exceptional collaboration with Linnaeus University, where the collaboration manifests the key concepts of curiosity, innovation, utility and proximity.
  • "Infomaker's collaboration with us goes well in line with how Linnaeus University wants to carry out collaborations in the region."
  • "Infomaker is collaborating with Linnaeus University in many ways ranging from sharing our knowledge with students to lifelong learning for Infomaker colleagues," said Peter Mnsson, Infomaker CTO.